FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2923964488> ?p ?o ?g. }

• W2923964488 endingPage "084" @default.
• W2923964488 startingPage "HSR19" @default.
• W2923964488 abstract "Background: Mutations in the epidermal growth factor receptor (EGFR) gene have been identified in 10%–50% of patients with non-small cell lung cancer (NSCLC). Exon 20 insertion mutations represent about 2%–10% of this group. Reports of real world experience of NSCLC patients with EGFR exon 20 insertion mutations are limited. This study describes patient characteristics, treatment patterns, and survival outcomes of NSCLC patients with EGFR exon 20 insertions based on real world data. Methods: Flatiron Health electronic health record data, largely from community oncology practices, from January 2011–April 2018 were used for this retrospective observational study. Treatment-naïve (TN) and relapsed/refractory (RR) second-line patients diagnosed with NSCLC with EGFR exon 20 insertion mutation aged ≥18 years at treatment initiation were included. Patient characteristics were described, and Kaplan-Meier analyses were used to assess real world overall survival (rwOS) separately for TN (starting at first-line therapy) and RR (starting at second-line therapy) patients. Results: There were 128 TN and 71 RR patients identified. Median age was 66.5 and 65.0 years for TN and RR patients, respectively, and over half were female (TN: 59.4%, RR: 53.5%). Among 83 TN and 47 RR patients with known ECOG score at advanced diagnosis, most had score 0–1 (TN: 56.3%; RR: 62.0%). Central nervous system metastases were observed in 35.2% of TN and 33.8% of RR patients. While 45.3% of TN patients received any chemotherapy, approximately 20% of both TN and RR patient groups had exposure to various EGFR TKIs. Overall, median rwOS was low at 14.6 months for TN patients, and 10.1 months for RR patients. Conclusion: Real world survival of patients with EGFR exon 20 NSCLC remains poor. Treatment with any chemotherapy regimen was most commonly used followed by EGFR TKIs in TN patients, while the proportion treated with chemotherapy and EGFR TKIs was similar in RR patients. Despite limited evidence in this population, over a fifth of TN and RR patients received EGFR TKI monotherapy. This study demonstrated unmet need for improved therapeutic options in TN and RR patients with NSCLC with EGFR exon 20 insertion mutation." @default.
• W2923964488 created "2019-04-01" @default.
• W2923964488 creator A5011177968 @default.
• W2923964488 creator A5013551992 @default.
• W2923964488 creator A5040417897 @default.
• W2923964488 creator A5049944206 @default.
• W2923964488 creator A5060404340 @default.
• W2923964488 creator A5063896009 @default.
• W2923964488 creator A5076073842 @default.
• W2923964488 creator A5079590292 @default.
• W2923964488 creator A5090629674 @default.
• W2923964488 date "2019-03-08" @default.
• W2923964488 modified "2023-09-27" @default.
• W2923964488 title "HSR19-084: Real-World Treatment Patterns and Clinical Outcomes in Non-Small Cell Lung Cancer Patients with EGFR Exon 20 Insertion Mutations" @default.
• W2923964488 doi "https://doi.org/10.6004/jnccn.2018.7200" @default.
• W2923964488 hasPublicationYear "2019" @default.
• W2923964488 type Work @default.
• W2923964488 sameAs 2923964488 @default.
• W2923964488 citedByCount "6" @default.
• W2923964488 countsByYear W29239644882020 @default.
• W2923964488 countsByYear W29239644882021 @default.
• W2923964488 countsByYear W29239644882022 @default.
• W2923964488 crossrefType "journal-article" @default.
• W2923964488 hasAuthorship W2923964488A5011177968 @default.
• W2923964488 hasAuthorship W2923964488A5013551992 @default.
• W2923964488 hasAuthorship W2923964488A5040417897 @default.
• W2923964488 hasAuthorship W2923964488A5049944206 @default.
• W2923964488 hasAuthorship W2923964488A5060404340 @default.
• W2923964488 hasAuthorship W2923964488A5063896009 @default.
• W2923964488 hasAuthorship W2923964488A5076073842 @default.
• W2923964488 hasAuthorship W2923964488A5079590292 @default.
• W2923964488 hasAuthorship W2923964488A5090629674 @default.
• W2923964488 hasConcept C104317684 @default.
• W2923964488 hasConcept C121608353 @default.
• W2923964488 hasConcept C126322002 @default.
• W2923964488 hasConcept C143998085 @default.
• W2923964488 hasConcept C167135981 @default.
• W2923964488 hasConcept C2776256026 @default.
• W2923964488 hasConcept C2776694085 @default.
• W2923964488 hasConcept C2779438470 @default.
• W2923964488 hasConcept C2781230642 @default.
• W2923964488 hasConcept C36823959 @default.
• W2923964488 hasConcept C54355233 @default.
• W2923964488 hasConcept C71924100 @default.
• W2923964488 hasConcept C86803240 @default.
• W2923964488 hasConceptScore W2923964488C104317684 @default.
• W2923964488 hasConceptScore W2923964488C121608353 @default.
• W2923964488 hasConceptScore W2923964488C126322002 @default.
• W2923964488 hasConceptScore W2923964488C143998085 @default.
• W2923964488 hasConceptScore W2923964488C167135981 @default.
• W2923964488 hasConceptScore W2923964488C2776256026 @default.
• W2923964488 hasConceptScore W2923964488C2776694085 @default.
• W2923964488 hasConceptScore W2923964488C2779438470 @default.
• W2923964488 hasConceptScore W2923964488C2781230642 @default.
• W2923964488 hasConceptScore W2923964488C36823959 @default.
• W2923964488 hasConceptScore W2923964488C54355233 @default.
• W2923964488 hasConceptScore W2923964488C71924100 @default.
• W2923964488 hasConceptScore W2923964488C86803240 @default.
• W2923964488 hasIssue "3.5" @default.
• W2923964488 hasLocation W29239644881 @default.
• W2923964488 hasOpenAccess W2923964488 @default.
• W2923964488 hasPrimaryLocation W29239644881 @default.
• W2923964488 hasRelatedWork W1591408781 @default.
• W2923964488 hasRelatedWork W2055244776 @default.
• W2923964488 hasRelatedWork W2350207578 @default.
• W2923964488 hasRelatedWork W2369505912 @default.
• W2923964488 hasRelatedWork W2413020017 @default.
• W2923964488 hasRelatedWork W3029222855 @default.
• W2923964488 hasRelatedWork W4313472722 @default.
• W2923964488 hasRelatedWork W4320928914 @default.
• W2923964488 hasRelatedWork W4382073703 @default.
• W2923964488 hasRelatedWork W2597201175 @default.
• W2923964488 hasVolume "17" @default.
• W2923964488 isParatext "false" @default.
• W2923964488 isRetracted "false" @default.
• W2923964488 magId "2923964488" @default.
• W2923964488 workType "article" @default.